Effect of physician-and pharmacist-cooperated intervention for lowering blood pressures among hypertensive patients.

Effect of physician-and pharmacist-cooperated intervention for lowering blood pressures among hypertensive patients. - PaPrica study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000749

Enrollment

150

Registered

2007-06-27

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

Standard medical care Intensive care (with pharmacist-led health promotion)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients taking antihypertensive medication. - Untreated subjects with SBP of 140-179 mmHg and/or DBP 90-109 mmHg in a health screening or at clinic.

Exclusion criteria

Exclusion criteria: - Secondary hypertension. - Severe renal failure or nephrotic syndrome. - Past history or under treatment of any cardiovascular disease. - Diabetes mellitus requiring medication. - Rheumatism or endocrine disease. - Exercise restriction over 20-min brisk walking or cycling per a day. - Other patients judged unsuitable for the study by physician.

Design outcomes

Primary

Measure	Time frame
1) Blood pressure at clinic and home 2) Distribution of cessation or decrease of antihypertensive medications End point was variable change form baseline at 24 weeks.	—

Secondary

Measure	Time frame
1) Urinary sodium and sodium reduction score 2) Regression of cardiovascular risk factors; obesity (waist circumference and BMI), prevalence of smoking, dyslipidemia, and prevalence of heavy alcohol drinking habit 3) Serum lipid: HDL cholesterol, LDL cholesterol, triglyceride 4) Liver function: gamma-GTP 5) Renal function: urinary microalbumin, creatinine, uric acid, and BUN 6) Glucose metabolism: HbAlc 7) Life style questionnaire score, SF-36 questionnaire score, and QOL score for antihypertensive medication 8) Costs and benefits of physician-and pharmacist-cooperated intervention	—

Measure

Time frame

1) Urinary sodium and sodium reduction score 2) Regression of cardiovascular risk factors; obesity (waist circumference and BMI), prevalence of smoking, dyslipidemia, and prevalence of heavy alcohol drinking habit 3) Serum lipid: HDL cholesterol, LDL cholesterol, triglyceride 4) Liver function: gamma-GTP 5) Renal function: urinary microalbumin, creatinine, uric acid, and BUN 6) Glucose metabolism: HbAlc 7) Life style questionnaire score, SF-36 questionnaire score, and QOL score for antihypertensive medication 8) Costs and benefits of physician-and pharmacist-cooperated intervention

—

Countries

Japan

Contacts

Public ContactHiroko Tobari

Osaka University, Graduate School of Medicine Public Health, Department of Social and Environmental Medicine

h-tobari@umin.ac.jp06-6879-3911

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026